Here is a thorough overview of how hypertension is defined according to the current (2025) guidelines, with comparisons across major international bodies:
Hypertension - Definition According to New Guidelines
The Core Concept
Any threshold defining hypertension is, to some extent, arbitrary. Blood pressure (BP) follows a roughly normal distribution in the population, and the risk of cardiovascular death rises continuously from BP levels as low as 115/75 mmHg - there is no "safe" cut-off point. An increase of 20 mmHg in systolic BP (SBP) or 10 mmHg in diastolic BP (DBP) is associated with a doubling of mortality from heart disease or stroke across all age groups 40-89 years. (Comprehensive Clinical Nephrology, 7th Ed.)
Despite this continuous risk, guidelines define thresholds based primarily on where treatment confers net clinical benefit.
2025 ACC/AHA Guidelines (United States) - Most Recent
The 2025 ACC/AHA High Blood Pressure Guideline (released 2025, updating the landmark 2017 version) maintains the same classification framework as 2017:
| Category | Systolic BP | Diastolic BP |
|---|
| Normal | < 120 mmHg | AND < 80 mmHg |
| Elevated | 120-129 mmHg | AND < 80 mmHg |
| Stage 1 Hypertension | 130-139 mmHg | OR 80-89 mmHg |
| Stage 2 Hypertension | ≥ 140 mmHg | OR ≥ 90 mmHg |
| Severe Hypertension | > 180 mmHg | OR > 120 mmHg |
Key points from 2025 ACC/AHA:
- Hypertension is still diagnosed at ≥ 130/80 mmHg (same as 2017), reaffirming this lower threshold after 8 years of supporting evidence
- The term "hypertensive urgency" has been replaced with "severe hypertension" (BP > 180/120 mmHg without end-organ damage), with a shift away from rapid IV lowering toward scheduled oral medications and close monitoring
- Treatment target for most patients remains < 130/80 mmHg
- For high-risk patients (PREVENT score > 7.5%), an SBP target of < 120 mmHg is now encouraged
- The PREVENT calculator replaces the older Pooled Cohort Equations for 10-year CVD risk estimation
2024 ESC / 2023 ESH Guidelines (Europe)
The European societies (ESC and ESH) published separate guidelines in 2023-2024, and both use a higher threshold of ≥ 140/90 mmHg for diagnosing hypertension. European guidelines also define a "high-normal" or "elevated BP" category between 130-139/85-89 mmHg.
The
European guidelines comparison (Lauder et al., Nat Rev Cardiol 2025) identifies key consensus and divergence areas between the ESC and ESH, and between European and American approaches.
2025 Hypertension Canada Guidelines
Published in May-July 2025 in CMAJ and Canadian Family Physician (
PMID 40419299), these guidelines cover diagnosis and treatment of hypertension in adults in primary care.
Key Transatlantic Differences (2025)
| Feature | 2025 ACC/AHA (USA) | 2024 ESC / 2023 ESH (Europe) |
|---|
| Hypertension threshold | ≥ 130/80 mmHg | ≥ 140/90 mmHg |
| "Elevated BP" category | 120-129 / <80 mmHg | 130-139 / 85-89 mmHg ("high-normal") |
| Treatment target | < 130/80 mmHg | < 140/90 mmHg (general), lower in high-risk |
| Risk tool | PREVENT equation | SCORE2 / ESH-specific tools |
This means many individuals classified as Stage 1 hypertensive in the US would be labelled only as having "elevated" or "high-normal" BP under European criteria - a practically significant difference affecting millions of people.
Why the 130/80 Threshold Matters
The ACC/AHA position is supported by data showing that for every 10 mmHg reduction in SBP:
- Coronary heart disease risk falls by 17%
- Stroke risk falls by 27%
- Heart failure risk falls by 28%
- All-cause mortality falls by 13%
The 2025 ACC/AHA guideline states that ≥ 140/90 mmHg is the threshold above which treatment benefits nearly all adults, while ≥ 130/80 mmHg is where treatment is beneficial for those with established CVD, high 10-year CVD risk, diabetes, CKD, or persistent elevation after lifestyle changes.
Bottom line: In the most current US (ACC/AHA 2025) framework, hypertension is defined as BP ≥ 130/80 mmHg. European 2024 guidelines continue to use ≥ 140/90 mmHg. The practical focus of 2025 guidelines has shifted from simply asking "who has hypertension?" to "how do we best stratify risk and individualize treatment?" using updated tools like the PREVENT calculator.